All of Genisis Biotechnologies’ management team are dedicated to the research and development of medicinal marijuana and all have a single-minded approach to ensuring the continued advancement of its clinically proven benefits are maintained.
Chief Executive Officer
Clive Mendelson serves as our Chief Executive Officer and has more than 30 years of executive, operational and commercial leadership experience in the bio-pharmaceutical industry, particularly in leading CNS transdermal patch and gel products which has helped CAMM Pharmaceuticals develop their own products adopting similar dispensing methods.
Prior to Genisis Biotech, Clive served as CEO of two publicly traded companies. Most recently, he was the CEO of a bio-tech company which was acquired by one of the world’s largest pharmaceutical companies during a 5-year tenure.
He assisted with the company acquiring FDA approval of its lead product, which was the first transdermal patch for migraine, to pre-launch before successfully over-seeing the sale of the company. He has also served as the CEO of a NASDAQ listed pharmaceutical company, where under his leadership, sales grew from $42 million to more than $90 million in just 4 years and market capitalization increased from $200 million to more than $500 million.
Jeremy received a B.S. in Molecular Biology from the University of Toronto - Mississauga, a Ph.D. in Biochemistry from York University, and conducted his postdoctoral training in biophysics and biology at The Canadian Cancer Society Saskatchewan.
Drew Lancaster, Ph.D.
Head of Product Development
Dr. Lancaster is our Head of Product Development and is responsible for the day-to-day management of our research and development activities as well as supporting the commercialization of the company’s products.
Dr. Lancaster has over two decades of pharmaceutical development experience with an emphasis on project management, pharmacology and toxicology.
Dr. Lancaster also has more than 30 years of executive, development and operational experience in the bio-pharmaceutical industry, particularly in CNS product development including epilepsy, pain, depression and schizophrenia. He has been responsible for more than 10 regulatory submissions and approvals of new pharmaceutical products, including transdermal patch and gel products.
Prior to joining Genisis Biotech, Dr. Lancaster held scientific leadership roles with some of Canada’s leading medical institutions and also held research positions with privately owned and publicly listed pharmaceutical companies in the U.S.
Dr. Lancaster has a broad range of development experience, starting from early drug discovery and clinical trials through to regulatory approval and commercial launch. He completed his Ph.D. at the University of Alberta Faculty of Science.
Sarah Blackwall, Ph.D.
Director of Formulation Sciences
Dr. Sarah Blackwall, Ph.D., has more than 15 years of experience developing formulations of pharmaceuticals, biologicals, and vaccines for alternative routes of delivery, including sublingual, nasal, transdermal, and inhalation
Previously, Dr. Blackwall successfully led the effort to develop, achieve regulatory approval, and complete manufacturing of the first tincture and transdermal patch used in the treatment of severe pain relief.
Dr. Blackwall also led the formulation and spray-drying process development of the first inhaled dry powder measles vaccine to successfully complete a Phase 1 clinical trial. She has a broad experience in early-stage R&D, formulation and process development, and technology transfer for GMP manufacturing.
Prior to joining Genisis Biotech she served in a variety of executive roles with Pfizer for more than 20 years and has over-seen technical and project leadership roles at the McGill University, Quebec.
Dr. Blackwall graduated with a Ph.D. in Biochemistry and Genetics from York University, Toronto and conducted post-doctoral research at the Wilfrid Laurier University, Waterloo, Canada.
Martin Milligan, PharmD
Director of Medical Services
Martin Milligan, PharmD, has served as our Director of Medical Services since July 2011. Martin is a senior pharmaceutical executive with more than 30 years of experience in clinical development, medical affairs and commercialization in CNS therapy areas.
During his career, he has led numerous successful clinical development programs, regulatory approvals and product launches. Prior to joining Genisis Biotech, he served as head of Medical Affairs for a large NYSE listed medical research company.
There he was instrumental in the clinical development of their international medical affairs’ teams in neurology and psychiatry. Additionally, he led several successful commercial product launches for some of the more accepted medicines currently being used by psychiatrists worldwide. He earned his Doctor of Pharmacy degree at the University of British Columbia and his MBA at the Trinity Western University.
He has several published articles relating to the use of medical marijuana and the differing experiences between men and women who use medicinal marijuana for Parkinson’s disease tremor and has recently completed a clinical report on the findings.
Martin also serves on the Board of Visitors at The School of Pharmacy at the University of Waterloo and as a board member of several non-profit medical organizations.
Director of Corporate Development
Don Jennings serves as Genisis Biotech’s Director of Corporate Development. Mr. Jennings is a seasoned executive who has held management, financial and strategic planning roles in his 28-year tenure in the pharmaceutical industry.
Prior to Genisis Biotech, he was Senior Vice President, Chief Financial Officer, at one of the world’s most well-respected pharmaceutical giants and focused on their self-administered parenteral product range. He has also held the role of Chief Financial Officer with Auxilium Pharmaceuticals, as well as additional general management, business development and strategic planning responsibilities with them.
Mr. Jennings has over two decades of experience working with emerging growth companies and the investors that support them, including eight years as Vice President with a Canadian bio-tech company that he helped take public and sell for nearly $200 million.
Mr. Jennings holds a BS from the University of Manitoba and sits on several committees that explore the clinical benefits of medicinal marijuana for children.
Jonathon Rennie, PhD
Director of Cannabinoid Research
Dr. Jonathon Rennie, PhD, serves as our Director of Cannabinoid Research. Dr. Rennie is also an Adjunct Assistant Professor in the Department of Psychiatry at the McGill University, Montreal.
Prior to joining Genisis Biotech, he was a Research Health Science Specialist at the Canadian Centre on Substance Use and Addiction in Ottawa as well as sitting on the board at the National Center for Post-traumatic Stress Disorder, (PTSD), at The Life Line Canada Foundation. He is also the former Executive Director at the Institute for Research on Cannabinoids, (IROC), in Colorado Springs, Colorado.
As an early research pioneer of marijuana comorbidity, Dr. Rennie has spent over a decade investigating the interrelations between marijuana and a number of health conditions, including chronic pain, HIV, PTSD, and sleep disorders for the purposes of treatment development and refinement. His research has spanned from laboratory-controlled to clinical trials and pre-implementation. Dr. Rennie has published well over 100 peer-reviewed empirical publications, and he serves on the editorial boards of six scientific journals.
Dr. Rennie earned a BA in psychology and PhD in clinical psychology from the University of Toronto and has also completed a pre-doctoral clinical psychology internship at the Memorial University of Newfoundland and a joint postdoctoral fellowship at the Calgary Clinical Psychology institute.
Simon Hoffer has served as Genisis Biotech’s Commercial Director for nearly 7 years. Over his 25-year career in the pharmaceutical industry, Mr. Hoffer has held several leadership roles in marketing, sales, business development, analytics and alliance management.
Prior to Genisis Biotech, he was Director for Strategic Portfolio Management at Cipher Pharmaceuticals, a publicly-traded, Canadian-based dermatology company, where he managed the company’s global portfolio.
Mr. Hoffer also held various roles of increasing responsibility at a Montreal-based specialty bio-pharmaceutical company. In his last role as Executive Director, Corporate Development & Licensing with them, he participated in several transformational M&A, licensing and co-promotion deals through, and including, several international acquisitions.
Mr. Hoffer held senior managerial positions at several bio-science companies during the initial commercial build-out of the organization and spent over a decade at GlaxoSmithKline in various U.S. and global commercial roles within specialty markets, including the marketing of treatments for neurological conditions and epilepsy.
Mr. Hoffer received a B.A. double major in Political Science/Policy and Management Studies from Dickinson College in Carlisle, Pennsylvania.